NYMC Faculty Publications
Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression
Author Type(s)
Faculty
DOI
10.1155/2023/3291957
Journal Title
Canadian Respiratory Journal
First Page
3291957
Document Type
Article
Publication Date
1-1-2023
Department
Pathology, Microbiology and Immunology
Abstract
. Dysregulation of epithelial-mesenchymal transition (EMT) in the airway epithelium is associated with airway remodeling and the progression of pulmonary fibrosis. Many treatments have been shown to inhibit airway remodeling and pulmonary fibrosis progression in asthma and chronic obstructive pulmonary disease (COPD) by regulating EMT and have few side effects. This review aimed to describe the development of airway remodeling through the EMT pathway, as well as the potential therapeutic targets in these pathways. Furthermore, this study aimed to review the current research on drugs to treat airway remodeling and their effects on the EMT pathway. . The dysregulation of EMT was associated with airway remodeling in various respiratory diseases. The cytokines released during inflammation may induce EMT and subsequent airway remodeling. Various drugs, including herbal formulations, specific herbal compounds, cytokines, amino acid or protein inhibitors, microRNAs, and vitamins, may suppress airway remodeling by inhibiting EMT-related pathways.
Recommended Citation
He, H., Ji, X., Cao, L., Wang, Z., Wang, X., Li, X., & Miao, M. (2023). Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression. Canadian Respiratory Journal, 2023, 3291957. https://doi.org/10.1155/2023/3291957